Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsTo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MOREAll products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
During the past decades, CART therapy has achieved good results in hematoma, but the effect of CAR-T on solid tumors is not so obvious. The main reason is that T cells are difficult to infiltrate the solid tumor microenvironment and are easy to be depleted in the tumor microenvironment. As an important immune cell, macrophage has an infiltration rate of up to 50% in solid tumors, and it is often one of the first cells absorbed by solid tumors and can selectively kill cancer cells through phagocytosis. Based on the above features, several researchers have turned to CAR-M exploration. Compared with CAR-T therapy, CAR-M has good tumor invasion and the capability to change the tumor microenvironment. Meanwhile, macrophages do not need complex antigen recognition mechanisms and can directly engulf and eliminate those cells that appear abnormal, which is more likely to have an effect on solid tumors.
For CAR-M development, there are also some obstacles at present. Firstly, macrophages are naturally resistant to commonly used viral vectors. Macrophages serve as the body's first defense line against cancer cells and viruses, which makes it difficult to modify macrophages to attack cancer through common viral vectors. Secondly, the biggest problem lies in the tumor microenvironment of solid tumors, tumor-associated macrophages as a critical cell type in the tumor microenvironment, not only suppress the immune cell functions but also promote tumor growth. So, how to better balance the M1-M2 function will be an important difficulty. Thirdly, the problem of macrophage cell amplification. Unlike T cells, which can be cloned and expanded in large numbers in the laboratory, macrophages do not expand in vitro, and it is a great challenge to obtain a large number of macrophages.
Creative Biolabs has developed an innovative and proprietary platform for next-generation CAR-engineered macrophage cell therapies (CAR-MA) with great therapeutic potential for intractable solid tumors. Given the special characteristics of macrophages, our approach is to use the macrophages isolated from the primary monocytes, THP1 cell line or iPSC programmed macrophages, and genetically engineer them to express a CAR against the specific tumor antigen. The CAR-engineered macrophage cell products can be used for in vitro or in vivo phagocytosis assays to evaluate the CAR-MA efficacy. The macrophage cell types used for CAR engineering include:
Please feel free to contact us if you are interested in our following provided CARMA cell products. If the CARMA cell product of interest is not available in our product list, please send us an inquiry and our scientist will provide assistance to offer a custom-made CARMA cell product for you.
Associated Antigen Target
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
